Back to Blog
Summuary of the inn between5/7/2023 ![]() The origin substems were developed to classify antibodies based upon their “humanness”, and with the assumption that humanness correlates with immunogenicity in patients. The most widely used of these species origin substems are: -xi- for chimeric, -zu- for humanized and -u- for human. Substems were then developed in 1997 to describe the antibody origin. The “-mab” stem was introduced in 1990 to indicate monoclonal antibody-based therapeutics. The WHO selects INNs based upon the advice of an expert advisory panel. Additionally, the INN system supports communication and exchange of information among health professionals and scientists worldwide. This system serves the important function of providing clear identification, and safe prescription and dispensing of medicines to patients. The WHO established the INN system in 1950 to provide a unique (generic) name to identify each pharmaceutical substance. ![]() The presentation was followed by a panel discussion in which input was solicited from the audience of conference delegates. This session comprised an introductory presentation from Paul Carter based upon a recent publication by 34 authors from 31 different organizations 1. A town hall forum on antibody drug nomenclature was held at the 2015 Antibody Engineering & Therapeutics meeting to update delegates on changes to the INN definitions, discuss their consequences, and solicit input on potential next steps. Unfortunately the new definitions suffer from several major limitations that make them unworkable 1. ![]() A modification of the existing definitions was required because advances in antibody engineering have made classification into the current three main antibody groups (i.e., chimeric, humanized and human) unclear. In 2014 the World Health Organization (WHO) introduced new definitions for the assignment of antibody international nonproprietary names (INN). Meeting Report: The Diagnostic Landscape for COVID-19Īntibody Drug Nomenclature: What is INN a Name? WHO Has Been Changing Them?.Guide to “Coronavirus in the Crosshairs”.Snakebite antivenoms: Global challenges and progress toward recombinant antibody therapeutics.Antibodies in late-stage clinical studies.Antibody therapeutics approved or in regulatory review in the EU or US.Huston Antibody Science Talent Award Recipient AIRR Community Meeting IV: “Bridging the Gaps”.AIRR Community Special Event: “Response to COVID-19”.AIRR-seq Biological Standards and Workflows.AIRR Community Meeting V: “Zooming in to the AIRR Community”.AIRR Community Meeting VI: “Exploring New Frontiers”.AIRR Community Special Event 2023 – Zooming in to the Community II.Scientific Advisors, Antibody Engineering & Therapeutics Europe.Antibody Engineering & Therapeutics Europe 2023.2018 Antibody Engineering & Therapeutics.2019 Antibody Engineering & Therapeutics.2020 Antibody Engineering & Therapeutics.2022 Antibody Engineering & Therapeutics.Antibody Engineering & Therapeutics (US) 2023.Emerging Immunotherapeutics for Ovarian Cancer Symposium.Emerging Cancer Therapies Leveraging Gamma-Delta Effector T cells Symposium.Biopharmaceutical Informatics Symposium. ![]() Harnessing Cytokines for Cancer Immunotherapy Symposium.Computational Antibody Discovery Symposium Participants.Computational Antibody Discovery: State of the Art. ![]()
0 Comments
Read More
Leave a Reply. |